Spasmalgon, 5 ml 10 pcs

Spasmalgon is a spasmoanalgesic of combined composition.

Methamisole sodium is a derivative of pyrazolone. It has analgesic, antipyretic and anti-inflammatory effects, the mechanism of which is associated with inhibition of prostaglandin synthesis.

Pitophenone hydrochloride is a myotropic antispasmodic; it has a direct effect on the smooth muscles of internal organs and causes their relaxation.

Phenpiperinia bromide, being a m-cholinoblocker, has an additional relaxing effect on the smooth muscles.

The combination of the three components of the drug leads to a mutual enhancement of their pharmacological action.

Indications

Pain syndrome (mild or moderate) with spasms of smooth muscles of internal organs: renal colic, spasm of the ureters and bladder; biliary colic intestinal colic biliary dyskinesia postcholecystectomy syndrome chronic colitis; algodismenorrhea diseases of the pelvic organs.

Pharmacological effect

Spazmalgon is a combined antispasmodic analgesic.

Metamizole sodium is a pyrazolone derivative. It has analgesic, antipyretic and anti-inflammatory effects, the mechanism of which is associated with inhibition of prostaglandin synthesis.

Pitophenone hydrochloride is a myotropic antispasmodic, has a direct effect on the smooth muscles of internal organs and causes its relaxation.

Phenpiverinium bromide, being an m-anticholinergic blocker, has an additional relaxing effect on smooth muscles.

The combination of the three components of the drug leads to a mutual enhancement of their pharmacological action.

Special instructions

In patients suffering from bronchial asthma, taking the drug can provoke the development of an attack.

When using the drug, it is necessary to monitor the peripheral blood picture (leukocyte content) and the functional state of the liver.

If agranulocytosis is suspected or thrombocytopenia is present, the drug should be discontinued.

During treatment with the drug, you should not drink alcohol.

The effect of the drug on the ability to drive vehicles and other mechanisms that require increased concentration

During treatment, it is not recommended to drive vehicles or engage in potentially hazardous activities that require quick physical and mental reactions.

Active ingredient

Metamizole sodium, Pitophenone, Fenpiverinium bromide

Composition

1 ml of solution contains:

active substances:

metamizole sodium 500.0 mg, fenpiverinium bromide – 0.02 mg, pitofenone hydrochloride – 2.0 mg.

Excipients: water for injection – up to 1 ml.

Pregnancy

Systematic use of the drug in the first and last trimester of pregnancy and during breastfeeding is excluded. If the use of the drug cannot be avoided, breastfeeding should be stopped for this period of time.

Contraindications

Hypersensitivity to the components of the drug and other pyrazolone derivatives inhibition of bone marrow hematopoiesis severe liver and/or renal failure deficiency of glucose-6-phosphate dehydrogenase tachyarrhythmias severe angina pectoris decompensated chronic heart failure angle-closure glaucoma prostatic hyperplasia (with clinical manifestations) intestinal obstruction megacolon collapse pregnancy (especially in I trimester and in the last 6 weeks) lactation period – children up to 15 years of age.
With caution:

Kidney/liver failure; bronchial asthma; bronchial asthma, urticaria or acute rhinitis provoked by taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs, tendency to arterial hypotension, hypersensitivity to other non-steroidal anti-inflammatory drugs.

Side Effects

From the urinary system: impaired renal function, oliguria, anuria, proteinuria, interstitial nephritis, red staining of urine.

Allergic reactions: urticaria (including on the conjunctiva and mucous membranes of the nasopharynx), angioedema in rare cases – malignant exudative erythema (Steven-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome), bronchospastic syndrome, anaphylactic shock.

From the hematopoietic organs: agranulocytosis, leukopenia, thrombocytopenia. Other: decreased blood pressure (BP).

Anticholinergic effects: dry mouth, decreased sweating, accommodation paresis, tachycardia, difficulty urinating.

Local reactions: with intramuscular administration, infiltrates at the injection site are possible.

Interaction

The simultaneous use of Spazmalgon with other non-narcotic analgesics can lead to mutual enhancement of toxic effects.

Sedatives and tranquilizers enhance the analgesic effect of metamizole sodium.

Tricyclic antidepressants, oral contraceptives, and allopurinol disrupt the metabolism of metamizole in the liver and increase its toxicity.

Barbiturates, phenylbutazone and other inducers of microsomal liver enzymes weaken the effect of metamizole sodium.

Radiocontrast drugs, colloidal blood substitutes and penicillin should not be used during treatment with drugs containing metamizole sodium.

Simultaneous use with cyclosporine reduces the level of the latter in the blood.

Metamizole sodium, displacing oral hypoglycemic drugs, indirect anticoagulants, glucocorticoids and indomethacin from its binding to plasma proteins, can increase the severity of their action.

When used together with H1-histamine receptor blockers, butyrophenones, phenothiazines, tricyclic antidepressants, amantadine and quinidine, the m-anticholinergic effect may be enhanced.

Enhances the effects of ethanol.

Concomitant use with chlorpromazine or other phenothiazine derivatives can lead to the development of severe hyperthermia.

Thiamazole and cytostatics increase the risk of developing leukopenia. The effect is enhanced by codeine, H2-histamine receptor blockers and propranolol (slows down the inactivation of metamizole sodium).

If it is necessary to use the above and other medications simultaneously, you should consult your doctor.

Overdose

Symptoms: vomiting, dry mouth, decreased sweating, impaired accommodation, decreased blood pressure, drowsiness, confusion, impaired liver and kidney function, convulsions.

Treatment: gastric lavage, administration of activated carbon, symptomatic therapy.

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25°C.
Keep out of the reach of children.

Shelf life

3 years.

Manufacturer

Sopharma JSC, Bulgaria